Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Conditions

• Efficacy and Safety

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• apatinib — DRUG
  The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
• temodar — DRUG
  dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d

Study Details

The patient was given a daily dose of apatinib 500mg (or based on weight). Individualized chemotherapy regimens were given based on molecular expression and prior chemotherapy.

Key Dates

Start date

Mar 3, 2016

Status verified

Apr 2019

Primary completion

Jan 3, 2017

Completion

Jan 6, 2018

Study Design

Enrollment

25 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: apatinib 500mg

Primary Outcome Measure

Response to treatment [ Time Frame: up to 3 months ]